Accueil   Diary - News   All news Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism

Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism

 

 

AZP-3601 is an Parathyroid Hormone Analog for Hypoparathyroidism 

 

LYON, France, and NEWTON, MA, October 14, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global clinical-stage company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the first subject in the Phase 1 clinical trial for AZP-3601 has been dosed. AZP-3601 is currently in development for the treatment of hypoparathyroidism, a rare and potentially debilitating endocrine disorder. AZP-3601 is a parathyroid hormone (PTH) analog that targets a specific configuration of the PTH receptor, thereby inducing a prolonged increase in blood calcium levels.

 

 

“This achievement marks a significant milestone for Amolyt Pharma in the development of AZP-3601,” said Thierry Abribat, Ph.D., chief executive officer. 

 

Read the press release